Analgesics: Market Research Report

October 2010 | 767 pages | ID: A96AACC324FEN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Analgesics in US$ Million by the following segments: Internal Analgesics, (Aspirin, Acetaminophen, Ibuprofen, and Others (includes combination drugs)), and External Analgesics.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2007 through 2015.

A six-year historic analysis is also provided for these markets.

The report profiles 137 companies including many key and niche players such as Bayer Consumer Care, Johnson & Johnson, McNeil Consumer Healthcare, Novartis International AG, Pfizer, Inc., Reckitt Benckiser Group Plc, and Sanofi Aventis S.A.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

1. INTERNAL ANALGESICS

Aspirin
Acetaminophen
Ibuprofen
Others

2. EXTERNAL ANALGESICS

2. GLOBAL ANALGESICS MARKET OVERVIEW

Pain Therapeutic Market
Analgesics Market - Offering Immense Potential
Internal Analgesics – The Largest & Fastest Growing Market
Liquid Analgesics Register Rapid Growth
Neuropathic Pain - Unexplored
Ibuprofen Scoring High
External Analgesics – Loosing Sheen
Topical Analgesics Market: Current Picture
Competitive Scenario
Global Analgesics Market (2007): Leading Analgesics Brands by Manufacturer

3. PRODUCT OVERVIEW

A Brief History
Analgesics
Definition
Types of Pain
Acute Pain
Chronic Pain
Drugs Combating Pain
Local Anesthetics
Narcotic Opioids
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Types of NSAIDS
Common NSAIDs
Clinical Use...
Side Effects...
Aspirin
The Wonder Drug...
PolyAspirin: The Safer and More Potent Polymer Variant of Aspirin
Mode of Action
Contraindications
Acetaminophen
Acetaminophen Protects Heart Muscle
Acetaminophen Reduces Incidence of Ovarian Cancer
Ibuprofen, Ketoprofen and Naproxen
Combination Analgesics

Table 1. Opioid Analgesics Market: Percentage Share of Opioid / Acetaminophen Combination Products in the Opioid Script Volume (includes corresponding Graph/Chart)

OTC Analgesics: An Overview

4. INDUSTRY DYNAMICS

Escalating R&D Costs: A Boon or Bane?
Timeline of the Drug Approval Process
Cox II Crisis Tarnishes Industry Growth
Novel Therapies to Propel Opioid and Non-Opioid Therapies
Rx-to-OTC Switch
Why Consumers Prefer OTC Drugs?
Development of Analgesic Tripeptides

5. RECENT CLINICAL TRIALS

PLx Initiates Clinical Trial For Aspirin-PC
Neurodiscovery Receives Approval for NSL-101 Phase II Clinical Trials

6. PRODUCT INTRODUCTIONS/INNOVATIONS

Victory Pharma Unveils Naprelan Dose Card
Nutra Pharma Commences Online Sales of Cobroxin
Nutra Pharma to Introduce Nyloxin Rx
Dr Reddy’s Rolls Out Finrid
MIP Technologies and Supelco Introduce Unique SPE Product
Novartis Introduces Voltaren AC Product Line
ProEthic Pharmaceuticals Releases Ibudone for Acute Pain Management
Dr. Reddy’s Laboratories Introduces Supanac for Acute Pain Management
Teva Pharmaceutical Announces the Launch of Fentanyl Transdermal System
Dr. Reddy's Laboratories Introduces Supanac NSAID Drug

7. PRODUCT INNOVATIONS/LAUNCHES IN RECENT PAST - A PERSPECTIVE BUILDER

Mallinckrodt Introduces Magnacet™ Tablets for Pain Management
Wockhardt to Launch New Painkiller
Paladin Labs and Labopharm Introduce Tridural™
Shionogi & Co Introduces OxiNorm Powder 0.5%
McNeil Brings Chewable TYLENOL® GoTabs Tablets
Barr Unveils Generic Version of ACTIQ®
Novartis Launches Voltarol Pain-Eze Emulgel.
TheraQuest Launches TQ-1017
Mentholatum Company Introduces WellPatch Deep Heat Patch…

8. PRODUCT APPROVALS

Par Pharmaceutical Secures Approval for Marketing Tramadol ER
Cipher Acquires Tentative Approval for Tramadol ER Capsules
Lannett Receives Approval for Developing Hydromorphone Hydrochloride Tablets
King Pharmaceuticals Receives Approval for Embeda Pain-Relief Capsules
Sangart Secures EC’s Orphan Drug Designation for MP4CO
Biovail Secures Canadian Approval for Ralivia
Elite Pharmaceuticals and PharmaNetwrok Receive FDA Approval

9. RECENT INDUSTRY ACTIVITY

China Life Insurance Inks Agreement with Sino Biopharmaceutical
Azur Pharma Inks Agreement with Elan Pharmaceuticals
Pfizer Acquires Wyeth
Taisho Pharmaceutical Takes Over OTC Drugs Business of Bristol-Myers Squibb
Piramal Healthcare Acquires Minrad International
Biocon Acquires Bulk Pharmaceuticals Unit of Hindujas
Abbott Acquires PG110 from PanGenetics
Sanofi-aventis Mexico Takes Over Laboratorios Kendrick
WraSer Acquires e5 Pharma’s Trezix
Astellas Acquires Exclusive rights to Pain-Relief Drug from Neuroges
Henan Lingrui Pharma Commences Construction of New Analgesic Factory
Labopharm Europe Enters into Agreement with Merck Sharp & Dohme
Cumberland Pharmaceuticals Enters into a Commercialization Agreement with DB Pharm Korea
Cumberland Pharmaceuticals Inks an Exclusive Agreement with Phebra
Mallinckrodt Acquires Rights of Exalgo Extended-Release Tablets from Neuromed
Labopharm Europe and Grunenthal Sign Distribution and Supply Agreement
Timm Medical and Ferring Co-promote Prosed DS in the US
Competitive Technologies and Fintrade Medical Ink Sales and Distribution Agreement
Accumetrics and Endotech Ink Exclusive Distribution Agreement
Astellas and NeurogesX Sign Distribution and Marketing Agreement
Akela Pharma Inks Agreement with Teikoku Seiyaku
Medical Nutrition Inks Exclusive Licensing Agreement with DSE Healthcare
Echo Therapeutics Inks a Licensing Deal with Ferndale Pharma
Circ Pharma Signs a Development Agreement with Elan
Orexo Inks Distribution Agreement with Neopharm
Orexo Inks Agreement with NovaMed Pharmaceuticals
Pharmos and Reperio Enter into Agreement
Caraco Pharmaceutical Launches Oxycodone Hydrochloride Tablet
Purdue Pharma Provides Labopharm’s RYZOLT
Bayer Acquires Sagmel’s OTC Business
E5 Pharma Receives Approval from FDA
Pharmaceutical Associates Receives Approval from FDA
Concord Receives New Drug Approvals
Hisamitsu Receives Approval for SALONPAs®
Johnson & Johnson Submits NDA to FDA
Nycomed and Paladin Inks Joint-Promotion Agreement for Tridural
Akela Extends Agreement with Janssen
Daiichi and Lead Chemical Receives Approval for Loxonin( Tape
Tokio Marine Capital Acquires Showa Yakuhin Kako
Corgenix Collaborates with Randox Laboratories
Corgenix Receives EPO Approval for Aspirin Resistance Method
IOL to Expand Production Capacity
American Oriental Bioengineering Partners with China Aoxing
Abraxis Takes Over Shimoda and its Subsidiary Company
Church & Dwight Snaps Up Del Pharmaceuticals from Coty
Sosei Group Corp Re-Acquires Rights to Commercialize AD 923
ProStrakan Group Inks Agreement with Paladin Labs
Anika Therapeutics Inks Distribution Agreement with DePuy Mitek
Wyeth Acquires ThermaCare Brand from P&G
Albemarle Appoints Dr. Reddy’s as Distributor of Bulk Ibuprofen API
Competitive Technologies and ELS Join Forces to Distribute Pain Management Device
Altea Therapeutics Partners with Hospira
Paladin Inks Co-Promotion Deal with Nycomed
AstraZeneca to Divest OTC Portfolio

10. CORPORTAE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER

Ranbaxy Receives Approval from FDA
Wockhardt Receives FDA Approval for DPN + APAP
Alpharma to Market Flector® Patch in the US
Auriga and Mikart Inks Agreement to Market Codein
Watson Receives FDA Approval for Oxycodone Hydrochloride and Ibuprofen
Labopharm’s Tramadol Receives Approval in Canada
Lion Acquires BUFFERIN® Trademark Rights
Grunenthal’s Extends Licensing Agreement with Ortho-McNeil
China Aoxing Pockets LRT
Anesiva Inks Joint Venture Agreement Wanbang
Beijing Med-Pharm Inks Agreement with Lotus Healthcare
LAB International Inks Licensing Agreement with Janssen Pharmaceutica
Three Sixty Pockets Rockford-Montgomery Labs
Antares Enters into License and Development Agreement for Opioid Analgesic
Abraxis BioScience Acquires AstraZeneca’s Analgesic Brand Portfolio
IntelliPharmaCeutics Inks Agreement with Larasan
Ranbaxy and Ethypharm Ink In-licensing Agreement
Elite Collaborates with TPN to Co-develop Analgesic Drug
Novartis Acquires Hexal Company and Major Stake in Eon Labs….
NovaDel Pharma Receives Patent for Buccal Sprays Technology
Auxilium Pharmaceuticals Enters into a Licensing Agreement with PharmaForm…
EC Sanctions Sale of Elan’s Prialt
EpiCept Corp. Merges with Maxim Pharmaceuticals, Inc
Reckitt Benckiser plc Acquires Boots Healthcare International…

11. FOCUS ON SELECT KEY PLAYERS

Bayer Consumer Care (US)
Johnson & Johnson (US)
McNeil Consumer Healthcare (Canada)
Novartis International AG (Switzerland)
Pfizer Inc. (US)
Reckitt Benckiser Group Plc (UK)
Sanofi Aventis S.A. (France)

12. GLOBAL MARKET PERSPECTIVE

Table 2. World Recent Past, Current & Future Analysis for Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 3. World Historic Review for Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 4. World 11-Year Perspective for Analgesics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years2005,2010 & 2015(includes corresponding Graph/Chart)

Table 5. World Recent Past, Current & Future Analysis for Internal Analgesics by Geographic Region/ Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 6. World Historic Review for Internal Analgesics by Geographic Region / Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 7. World 11-Year Perspective for Internal Analgesics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)

Table 8. World Recent Past, Current & Future Analysis for Internal Analgesics by Product Segment – Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 9. World Historic Review for Internal Analgesics by Product Segment – Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 10. World 11-Year Perspective for Internal Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Aspirin, Acetaminophen, Ibuprofen, and Others Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)

Table 11. World Recent Past, Current & Future Analysis for Aspirin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 12. World Historic Review for Aspirin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 13. World 11-Year Perspective for Aspirin by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005,2010& 2015 (includes corresponding Graph/Chart)

Table 14. World Recent Past, Current & Future Analysis for Acetaminophen by Geographic Region/ Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 15. World Historic Review for Acetaminophen by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 16. World 11-Year Perspective for Acetaminophen by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005,2010 & 2015 (includes corresponding Graph/Chart)

Table 17. World Recent Past, Current & Future Analysis for Ibuprofen by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 18. World Historic Review for Ibuprofen by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 19. World 11-Year Perspective for Ibuprofen by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005,2010 & 2015 (includes corresponding Graph/Chart)

Table 20. World Recent Past, Current & Future Analysis for Other Internal Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 21. World Historic Review for Other Internal Analgesics by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 22. World 11-Year Perspective for Other Internal Analgesics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years2005,2010 & 2015 (includes corresponding Graph/Chart)

Table 23. World Recent Past, Current & Future Analysis for External Analgesics by Geographic Region/ Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 2015 (includes corresponding Graph/Chart)

Table 24. World Historic Review for External Analgesics by Geographic Region / Country – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2007 (includes corresponding Graph/Chart)

Table 25. World 11-Year Perspective for External Analgesics by Geographic Region /Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years2005,2010 & 2015(includes corresponding Graph/Chart)

13. THE UNITED STATES

A. Market Analysis
Current and Future Analysis
Pain Statistics in the US
Industry Overview
Internal Analgesics
Cox-2 Drugs in for Some Trouble
Switch to OTC Drugs

Table 26. US Analgesics Market (2009): Percentage Share Breakdown of Leading Manufacturers by Sales (includes corresponding Graph/Chart)

Table 27. US Internal Liquid Analgesics Market (2009): Percentage Share Breakdown of Leading Brands by Sales (includes corresponding Graph/Chart)

Table 28. US Internal Tablet Analgesics Market (2009): Percentage Share Breakdown of Leading Brands by Sales (includes corresponding Graph/Chart)

Table 29. Internal Analgesics Market in the US by Retail Channel (2008): Percentage Share by Value Sales for Discount Stores, Food/Drug Combination Stores, Chain Drug Stores, Supermarkets, and Independent Drug Stores (includes corresponding Graph/Chart)

Promotional Strategies for the Internal Analgesics

Table 30. Market for Internal Liquid Analgesics in the U.S. by Retail Channel (2008): Percentage Share by Value Sales for Supermarkets, Drug Stores, and Discounters (includes corresponding Graph/Chart)

Pediatric Analgesics: The New Kid on the Block
External Analgesics
Stretching Boundaries

Table 31. US External Analgesics Market (2007): Percentage Share Breakdown of Leading Ten Brands by Revenues (includes corresponding Graph/Chart)

Table 32. External Analgesics Market in the US by Retail Channel (2008): Percentage Share by Value Sales for Chain drug stores, Discount stores, Food/drug combination stores, Independent drug stores, and Supermarkets (includes corresponding Graph/Chart)

Rubs, Patches: Driving the External Analgesics Market
Patch Relief…Gaining Momentum
B. Market Analytics

Table 33. US Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 34. US Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 35. US 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015(includes corresponding Graph/Chart)

14. CANADA

Market Analysis

Table 36. Canadian Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 37. Canadian Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 38. Canadian 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015(includes corresponding Graph/Chart)

15. JAPAN

A. Market Analysis
Current and Future Analysis
Competitive Scenario in the Past

Table 39. OTC Analgesics Market in Japan (2005): Market Share of Leading Players by Value – Lion, Arax, Taisho Pharmaceutical, SS Pharmaceutical, Shionogi, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 40. Japanese Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 41. Japanese Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 42. Japanese 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015 (includes corresponding Graph/Chart)

16. EUROPE

A. Market Analysis
Current and Future Analysis
By Product Group/Segment
European Pain Management Market
Generics Restrain Revenue Growth
Popular Brands in 2004

Table 43. Popular Brands of Pain & Inflammation Medication in Europe (2004): Percentage Share of Aspirin, Voltaren, Ibuprofen, Nurofen, Vioxx, Celebre, Tylenol, Aulin, Anadin, and Paracetamol (includes corresponding Graph/Chart)

B. Market Analytics

Table 44. European Recent Past, Current & Future Analysis for Analgesics by Geographic Region/Country – France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 45. European Historic Review for Analgesics by Geographic Region/Country – France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 46. European 11-Year Perspective for Analgesics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)

Table 47. European Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 48. European Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2007 (includes corresponding Graph/Chart)

Table 49. European 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)

16A.FRANCE

A. Market Analysis
Current and Future Analysis
Competitive Scenario

Table 50. Analgesics Market in France (2005): Market Share of Leading Players by Value – Bristol-Myers Squibb, Therapix, Roche, Bayer Group, Wyeth Consumer Healthcare, and Others) (includes corresponding Graph/Chart)

B. Market Analytics

Table 51. French Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 52. French Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 53. French 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015(includes corresponding Graph/Chart)

16B.GERMANY

A. Market Analysis
Current and Future Analysis
Competitive Scenario

Table 54. Analgesics Market in Germany (2005): Market Share of Leading Players by Value – Bayer Group, Boehringer Ingelheim, Wyeth Consumer Healthcare, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 55. German Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 56. German Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 57. German 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015(includes corresponding Graph/Chart)

16C.ITALY

A. Market Analysis
Current and Future Analysis
Competitive Scenario

Table 58. Analgesics Market in Italy (2005): Market Share of Leading Players by Value – Bayer Group, Angelini, Novartis, Bristol-Myers Squibb, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 59. Italian Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 60. Italian Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 61. Italian 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015 (includes corresponding Graph/Chart)

16D.THE UNITED KINGDOM

A. Market Analysis
Current and Future Analysis
An Overview of Analgesics Market in the UK
Distribution Scenario
Competitive Scenario

Table 62. Analgesics Market in the United Kingdom (2005E): Market Shares of Leading Players by Value – Boots Healthcare, GlaxoSmithKline, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 63. UK Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 64. UK Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 65. UK 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005,2010 & 2015(includes corresponding Graph/Chart)

16E.SPAIN

A. Market Analysis
Current and Future Analysis
Competitive Scenario

Table 66. Analgesics Market in Spain (2005): Market Share of Leading Players by Value – Bayer Group, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Boots Healthcare, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 67. Spanish Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 68. Spanish Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006(includes corresponding Graph/Chart)

Table 69. Spanish 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for2005,2010 & 2015 (includes corresponding Graph/Chart)

16F.REST OF EUROPE

Market Analysis

Table 70. Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 71. Rest of Europe Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 72. Rest of Europe 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

17. ASIA-PACIFIC

A. Market Analysis
Current and Future Analysis
The OTC Analgesic Market
OTC Analgesics Market in Asia-Pacific (2004): A Comparative Analysis of the Major Regions – Australia, China and South Korea
B. Market Analytics

Table 73. Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2007 through 2015 (includes corresponding Graph/Chart)

Table 74. Asia-Pacific Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 75. Asia-Pacific 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005,2010 & 2015(includes corresponding Graph/Chart)

18. LATIN AMERICA

Market Analysis

Table 76. Latin American Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 77. Latin American Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 78. Latin American 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart)

19. REST OF WORLD

Market Analysis

Table 79. Rest of World Recent Past, Current & Future Analysis for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 80. Rest of World Historic Review for Analgesics by Product Segment – Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 81. Rest of World 11-Year Perspective for Analgesics by Product Segment – Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

20.APPENDIX – POPULAR ANALGESIC BRANDS BY REGION

Canada
France
Germany
United Kingdom
Leading Analgesics Brands for Children
Italy
Spain
Rest of Europe
Asia-Pacific
Latin America
Competition
Total Companies Profiled: 137 (including Divisions/Subsidiaries - 179)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East
Africa


Please read Global Industry Analysts, Inc., - Sales Policy below before placing an order:
All Publications from Global Industry Analysts, Inc., (GIA) are protected per protocols of the Universal Copyrights Convention and the United States Copyrights Office. It is GIA’s policy that once purchased, these publications may not be returned for any reason. GIA makes all reasonable attempts to report current and accurate information in its publications.
GIA will not be responsible for any type of damages (financial or other) incurred by the client (company or individual) in the usage of GIA’s publications or services. The client agrees that in case a legal resolution becomes necessary, the venue shall be the city of San Francisco, California, USA. Under any circumstances, GIA’s liability shall be limited to the exact price of the product or service paid to GIA by the client.
This publication is sold as a single-user single-site license. Electronic versions operate like normal PDF files once installed and permit unlimited print and cut & paste. Digital controls and watermarks are set on electronic copies and are protected against copying. Extra licenses can be purchased for the same location at 10% of the list price.